Get access to our best features
Get access to our best features
Published 2 months ago

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

  • Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease, making it the first country with a rapidly aging population to have a treatment for the disease.
  • Leqembi, developed by Japanese drugmaker Eisai Co. And US biotechnology firm Biogen Inc., is designed for patients in the early stages of Alzheimer's, helping to slow their cognitive decline. The approval was announced by Prime Minister Fumio Kishida.
  • The number of dementia patients aged 65 or older in Japan is expected to rise to 7 million by 2025, highlighting the urgent need for treatments like Leqembi. Eisai Co. Is dedicated to providing this new treatment to individuals and their families.
Insights by Ground AI
Does this summary seem wrong?

29 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 43% of the sources are Center
45% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)